Skip to content Skip to footer
Serina Therapeutics (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, is scripting an uncommon chapter in biotech, bringing together seasoned leadership, investor-grade science, and strategic capital to tackle the field’s toughest clinical problems—all at a…